Tango Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision medicines to help patients with cancer through addressing the specific genetic alterations that fuel the cancer. Its lead program, TNG908, is a methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. It is also developing TNG462, a more potent and selective PRMT5 inhibitor with improved pharmacokinetic properties as compared to TNG908. TNG260 is a small molecule inhibitor of the CoREST deacetylase complex that reverses checkpoint inhibitor resistance in serine-threonine kinase 11 (STK11) mutant preclinical models. Its TNG348 is an allosteric inhibitor of ubiquitin-specific protease 1 (USP1) for the treatment of BRCA-mutant and other homologous recombination-deficient (HRD+) cancers.
